Showing 4271-4280 of 5646 results for "".
- Robert Califf Confirmed to Lead FDA for Second Timehttps://modernod.com/news/robert-califf-confirmed-to-lead-fda-for-second-time/2480645/The US Senate on Tuesday voted 50 to 46 in favor of confirming President Joe Biden nominee Robert Califf as commissioner of the FDA, a position he previously held under the Obama administration, according to a FiercePharma report.&
- Opthea Data for OPT-302 in Patients with Polypoidal Choroidal Vasculopathy (PCV) Presented at Angiogenesis 2022https://modernod.com/news/opthea-data-for-opt-302-in-patients-with-polypoidal-choroidal-vasculopathy-pcv-presented-at-angiogenesis-2022/2480640/Opthea announced data was presented at the Bascom Palmer 19th annual Angiogenesis, Exudation, and Degeneration 2022 Conference. The presentation, entitled “OPT-302 Combination Therapy with Ranibizumab for Treatment of Polypoidal Choroidal Vasculopathy,&r
- Regeneron Presents Encouraging Phase 2 Results for High-Dose Aflibercept 8 mg in Wet AMDhttps://modernod.com/news/regeneron-presents-encouraging-phase-2-results-for-high-dose-aflibercept-8-mg-in-wet-amd/2480636/Regeneron Pharmaceuticals announced results from its phase 2 proof-of-concept trial evaluating an investigational 8 mg high dose of aflibercept compared to the currently-approved 2 mg dose of Eylea (aflibercept) Injection in patients with wet age-related macular degeneration (AMD). The resul
- Waldo Announces the Acquisition of Placid0, Maker of Eye Assessment Apphttps://modernod.com/news/waldo-announces-the-acquisition-of-placid0/2480632/Waldo announces the acquisition of Placid0, maker of EASY, an eye assessment system mobile application. Financial terms of the deal were not disclosed. The acquisition is the next step in Waldo’s movement to make eye care an essential part of everyday life, with bo
- New 2-Year Data for Genentech’s Vabysmo and Susvimo Show Potential of Fewer Treatments for People With Wet AMD and DMEhttps://modernod.com/news/new-2-year-data-for-genentechs-vabysmo-and-susvimo-reinforce-potential-to-maintain-vision-with-fewer-treatments-for-people-with-wet-amd-and-dme/2480631/Genentech announced that new 2-year data from its phase 3 studies of Vabysmo (faricimab-svoa) and Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant will be presented at Angiogenesis, Exudation and Degeneration 2022 on February 12. These longer-term r
- Bausch Health Files for Solta IPOhttps://modernod.com/news/bausch-health-files-for-solta-ipo/2480629/Bausch Health Companies announced today that its wholly owned subsidiary, Solta Medical Corporation, has publicly filed for a proposed initial public offering (IPO). Solta, a provider of dermatology-focused lasers, has applied to list its common shares on the Nasdaq Global Select M
- Quantel Medical Launches C.STIM, a New Generation IPL System for Dry Eyehttps://modernod.com/news/quantel-medical-launches-a-new-generation-ipl-system-cstim/2480625/Quantel Medical announced the launch of C.STIM IPL system. Based on intense pulsed light technology, C.STIM is the new generation of IPL designed to treat the root causes of dry eyes: meibomian gland dysfunction, inflammation, and demodex. “Thanks to the unique
- Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operationshttps://modernod.com/news/outlook-therapeutics-expands-commercial-team-with-appointment-of-senior-vice-president-of-commercial-operations/2480623/Outlook Therapeutics, which is working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced the appointment of Joel Prieve as Senior Vice President, Commercial Operations.
- Alimera Sciences Announces Launch of Iluvien for Uveitis in Spainhttps://modernod.com/news/alimera-sciences-announces-launch-of-iluvien-for-uveitis-in-spain/2480619/Alimera Sciences announced that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, will launch Iluvien for noninfectious posterior uveitis in Spain, through its distribution partner, Brill Pharma (Brill). Brill has received a positive resolution fo
- Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Modelhttps://modernod.com/news/skye-bioscience-reports-potential-neuroprotective-benefit-of-sbi-100-in-preclinical-glaucoma-model/2480611/Skye Bioscience announced that in a preclinical study assessing the neuroprotective properties of its SBI-100 ophthalmic nanoemulsion, the treated group demonstrated a trend of retaining greater function of the eye’s retinal ganglion cells (RGCs) versus vehicle control. RGCs are cells